Phase IIIb, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 May 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ESSENCE
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 17 Feb 2017 Planned End Date changed from 1 Oct 2016 to 1 Jun 2017.
- 17 Feb 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2017.